GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 51-58

  Arias Pulido, Hugo ^a   Royce, Melanie ^a   Gong, Yun ^b   Joste, Nancy ^a   Lomo, Lesley ^a   Lee, Sang Joon ^a   Chaher, Nabila ^c   Verschraegen, Claire ^a   Lara, Juanita ^b   Prossnitz, Eric R ^a   Cristofanilli, Massimo ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Centre Pierre et Marie Curie   (Algeria)

Author keywords

Disease free survival; GPR30; Growth factor receptors; Hormone receptors; Inflammatory breast cancer; Overall survival

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR 30; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; EGFR PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASIAN; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CAUCASIAN; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TARGETING; ETHNIC DIFFERENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HISPANIC; HORMONE DEPENDENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEGRO; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77955774697     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0631-7     Document Type: Article

References (33)

1. PH Levine C Veneroso 2008 The epidemiology of inflammatory breast cancer Semin Oncol 35 11 16 10.1053/j.seminoncol.2007.11.018 18308141 (Pubitemid 351282398)
2. SE Singletary M Cristofanilli 2008 Defining the clinical diagnosis of inflammatory breast cancer Semin Oncol 35 7 10 10.1053/j.seminoncol.2007.11.010 18308140 (Pubitemid 351282390)
3. K Kerlikowske DL Miglioretti DSM Buist R Walker PA Carney 2007 Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population J Natl Cancer Inst 99 1335 1339 10.1093/jnci/djm111 17698950 (Pubitemid 47394172)
4. KW Hance WF Anderson SS Devesa HA Young PH Levine 2005 Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst 97 966 975 10.1093/jnci/dji172 15998949 (Pubitemid 41430562)
5. A Molckovsky B Fitzgerald O Freedman R Heisey M Clemons 2009 Approach to inflammatory breast cancer Can Fam Physician 55 25 31 19155362
6. M Panades IA Olivotto CH Speers T Shenkier TA Olivotto L Weir SJ Allan PT Truong 2005 Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis J Clin Oncol 23 1941 1950 10.1200/JCO.2005.06.233 15774787 (Pubitemid 46211373)
7. S Dawood N Ueno M Cristofanilli 2008 The medical treatment of inflammatory breast cancer Semin Oncol 35 64 71 10.1053/j.seminoncol.2007.11.012 18308147 (Pubitemid 351282392)
8. E Charafe-Jauffret C Tarpin P Viens F Bertucci 2008 Defining the molecular biology of inflammatory breast cancer Semin Oncol 35 41 50 10.1053/j.seminoncol.2007.11.015 18308145 (Pubitemid 351282395)
9. Y Gong 2008 Pathologic aspects of inflammatory breast cancer: Part 2. Biologic insights into its aggressive phenotype Semin Oncol 35 33 40 10.1053/j.seminoncol.2007.11.014 1:CAS:528:DC%2BD1cXktlOmtr0%3D 18308144 (Pubitemid 351282394)
10. AC Ventura SD Merajver 2008 Genetic determinants of aggressive breast cancer Annu Rev Med 59 199 212 10.1146/annurev.med.59.060106.184830 1:CAS:528:DC%2BD1cXis12ntbk%3D 17914925 (Pubitemid 351287933)
11. CM Revankar DF Cimino LA Sklar JB Arterburn ER Prossnitz 2005 A transmembrane intracellular estrogen receptor mediates rapid cell signaling Science 307 1625 1630 10.1126/science.1106943 1:CAS:528:DC%2BD2MXitV2is7c%3D 15705806 (Pubitemid 40354745)
12. P Thomas Y Pang EJ Filardo J Dong 2005 Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells Endocrinology 146 624 632 10.1210/en.2004-1064 1:CAS:528:DC%2BD2MXotlWitw%3D%3D 15539556 (Pubitemid 40129818)
13. EJ Filardo JA Quinn KI Bland AR Frackelton Jr 2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF Mol Endocrinol 14 1649 1660 10.1210/me.14.10.1649 1:CAS:528:DC%2BD3cXntVaksLk%3D 11043579
14. N Kanda S Watanabe 2003 17beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression J Invest Dermatol 121 1500 1509 10.1111/j.1523-1747.2003.12617.x 1:CAS:528: DC%2BD2cXhtVartQ%3D%3D 14675202 (Pubitemid 38005505)
15. N Kanda S Watanabe 2004 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression J Invest Dermatol 123 319 328 10.1111/j.0022-202X.2004.12645.x 1:CAS:528:DC%2BD2cXmtFKitLw%3D 15245432 (Pubitemid 38951827)
16. ER Prossnitz JB Arterburn HO Smith TI Oprea LA Sklar HJ Hathaway 2008 Estrogen signaling through the transmembrane G protein-coupled receptor GPR30 Annu Rev Physiol 70 165 190 10.1146/annurev.physiol.70.113006.100518 1:CAS:528:DC%2BD1cXkt1eqtrw%3D 18271749 (Pubitemid 351738176)
17. EJ Filardo JA Quinn AR Frackelton Jr KI Bland 2002 Estrogen action via the g protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis Mol Endocrinol 16 70 84 10.1210/me.16.1.70 1:CAS:528: DC%2BD38XhvVCitQ%3D%3D 11773440 (Pubitemid 34044499)
18. ER Prossnitz LA Sklar TI Oprea JB Arterburn 2008 GPR30: a novel therapeutic target in estrogen-related disease Trends Pharmacol Sci 29 116 123 1:CAS:528:DC%2BD1cXislKht7o%3D 18262661
19. EJ Filardo CT Graeber JA Quinn MB Resnick D Giri RA DeLellis MM Steinhoff E Sabo 2006 Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression Clin Cancer Res 12 6359 6366 10.1158/1078-0432.CCR-06-0860 1:CAS:528:DC%2BD28XhtFKitb7M 17085646 (Pubitemid 44799705)
20. Smith HA, Leslie K, Singh M, Qualls CR, Revankar CM, Joste N, Prossnitz ER (2007) GPR-30: a novel indicator of poor survival in endometrial carcinoma. Am J Obstet Gynecol 196:386.e381-386.e389
21. H Smith H Arias-Pulido D Kuo T Howard C Qualls S-J Lee C Verschraegen H Hathaway N Joste E Prossnitz 2009 GPR30 predicts poor survival for ovarian cancer Gynecol Oncol 114 465 471 10.1016/j.ygyno.2009.05.015 1:CAS:528:DC%2BD1MXptlSrt7o%3D 19501895
22. C Ginestier E Charafe-Jauffret F Bertucci F Eisinger J Geneix D Bechlian N Conte J Adelaide Y Toiron C Nguyen,, et al. 2002 Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers Am J Pathol 161 1223 1233 1:CAS:528:DC%2BD38Xotlyqu7c%3D 12368196
23. M Cristofanilli AU Buzdar GN Hortobagyi 2003 Update on the management of inflammatory breast cancer Oncologist 8 141 148 10.1634/theoncologist.8-2-141 1:CAS:528:DC%2BD3sXjsVOmt7w%3D 12697939 (Pubitemid 36428280)
24. N Cabioglu Y Gong R Islam KR Broglio N Sneige A Sahin AM Gonzalez-Angulo P Morandi C Bucana GN Hortobagyi,, et al. 2007 Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer Ann Oncol 18 1021 1029 10.1093/annonc/mdm060 1:STN:280:DC%2BD2szntVWitQ%3D%3D 17351259 (Pubitemid 47050493)
25. Y Gong D Booser N Sneige 2005 Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 103 1763 1769 10.1002/cncr.20987 1:CAS:528:DC%2BD2MXktFGnsbw%3D 15786420 (Pubitemid 40563246)
26. Lachin J (2000) Biostatistical methods. Wiley, New York, pp 272-285
27. EBCTCG 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
28. EJ Filardo P Thomas 2005 GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release Trends Endocrinol Metab 16 362 367 10.1016/j.tem.2005.08.005 1:CAS:528:DC%2BD2MXhtVart7fP 16125968 (Pubitemid 41338741)
29. W Kuo L Chang D Liu H Hwa J Lin P Lee C Chen H Lien R Yuan C Shun,, et al. 2007 The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population Taiwan J Obstet Gynecol 46 135 145 10.1016/S1028-4559(07)60007-2 17638621 (Pubitemid 47236783)
30. A-M Hui W Zhang W Chen D Xi B Purow GC Friedman HA Fine 2004 Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells Cancer Res 64 9115 9123 10.1158/0008-5472.CAN-04-2740 1:CAS:528:DC%2BD2cXhtVOmsLfK 15604281 (Pubitemid 40003793)
31. J Teng Z-Y Wang ER Prossnitz DE Bjorling 2008 The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation Endocrinology 149 4024 4034 10.1210/en.2007-1669 1:CAS:528:DC%2BD1cXptlamt78%3D 18467434
32. CG Bologa CM Revankar SM Young BS Edwards JB Arterburn AS Kiselyov MA Parker SE Tkachenko NP Savchuck LA Sklar,, et al. 2006 Virtual and biomolecular screening converge on a selective agonist for GPR30 Nat Chem Biol 2 207 212 10.1038/nchembio775 1:CAS:528:DC%2BD28XisFOnsbs%3D 16520733
33. M Dennis R Burai C Ramesh W Petrie S Alcon T Nayak C Bologa A Leitao E Brailoiu E Deliu,, et al. 2009 In vivo effects of a GPR30 antagonist Nat Chem Biol 5 421 427 10.1038/nchembio.168 1:CAS:528:DC%2BD1MXls1Cmtr0%3D 19430488